Disruption of the Mucus Barrier by Topically Applied Exogenous Particles

Abstract

The mucus barrier is well established as a formidable barrier to exogenous substances and forms the first line of defense for mucosal surfaces. Drugs and particle systems are known to be significantly hindered via a variety of interactions with mucus and some efforts have been reported that can mitigate these interactions. We investigated topically applied particulate systems (nano and micro) for their potential to interact with mucus and influence on the diffusion of model drugs across the mucus barrier. Functionalized polystyrene nanoparticles and microparticles and diesel particulate matter were topically applied to established in vitro mucus models. Particle treated mucus was then assessed, compared to controls, for drug permeation rates. The average permeation rate of drugs increased 2-fold following the application of particles to mucus compared to permeation of the same drug through mucus alone. In some cases permeation enhancement of small model drugs was over 5 times that of controls. Assessment of particle physicochemical properties also indicated that significant interactions occurred between mucus and the particles as determined by zeta potential changes and size changes. Collectively this work supports the hypothesis that topically applied particles interact with the mucus barrier causing disruption of this barrier allowing for increased drug permeation. These findings have implications for improved drug delivery and enhanced environmental exposure to exogenous substances.

Characterization of the Influence of Semen-Derived Enhancer of Virus Infection on the Interaction of HIV-1 with Female Reproductive Tract Tissues

“…It is possible that positively charged SEVI fibrils were destabilized in the unique aqueous environment of mucus, potentially influenced by the negatively charged mucins. The overall surface charge, or -potential, of HIV-1 is Ϫ3 to Ϫ4 mV, and the -potential for pig gastric mucin (PGM) is ϳϪ35 mV (20,30,33,34). Although we understand that PGM is not the same as human female genital mucin, it is likely to have similarities in -potential due to the negatively charged glycans that coat both PGM and endocervical mucins such as MUC5B.…”

Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery

“…For example, a study showed that rhodamine permeation was significantly different in mucin solution and in an artificial cystic fibrosis mucus model, because of the differences in the mucus model composition. 34 In our study, the closest model to human intestinal mucus model was chosen (ie, pig intestinal mucus). This model contained principally water, mucin, lipids, and proteins, making it more complex than mucin used alone or artificial mucus.…”

Polymer-based nanocarriers for vaginal drug delivery

“…NPs may in turn lead to the disruption of mucus with loss of its barrier properties [63][64]. As much as this could be eventually seen as favorable for drug transport, one should keep in mind the important physiological functions of mucosal fluids, namely in protecting against xenobiotics and pathogens [65][66].…”